REG - Cambridge Cognition - New Major Pharma Client for Schizophrenia Trials

Cambridge Cognition HoldingsAnnouncement

10/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nRSJ8378Xa&default-theme=true

RNS Number : 8378X  Cambridge Cognition Holdings PLC  10 January 2022

 

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition announces new major pharma client for schizophrenia
clinical trials

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
been awarded contracts for two clinical trials by a top 20 pharmaceutical
company to assess the pro-cognitive effects of a new drug in schizophrenia.
Together the contracts are worth £700,000 over two years. This is the second
pharmaceutical client to award Cambridge Cognition major contracts for
cognitive assessments for schizophrenia in the last year(1). Approximately 30
clinical trials on new drugs for schizophrenia run every year(2),
demonstrating the potential for further sales in this therapeutic area.

 

Cambridge Cognition offers cognitive assessments with the sensitivity to
measure the distinct cognitive processes impaired in schizophrenia, including
memory, attention and executive function. Between September 2020 and December
2021, the Company was contracted for six pivotal trials for another client's
new schizophrenia drug(1), earning Cambridge Cognition a reputation in the
field for delivering highly sensitive cognitive assessments. Now, this new
client, a top 20 pharmaceutical company has contracted Cambridge Cognition to
determine the efficacy of its new drug for improving cognition in patients
with schizophrenia and another indication. Cambridge Cognition will provide
its proprietary cognitive assessments (CANTAB(TM)), its electronic
questionnaires and scales platform (eCOA), and specialist, study management
services.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"It is excellent news that we have secured another top 20 pharmaceutical
company as a new client and that we are conducting more clinical trials for
patients with schizophrenia, which is a therapeutic area we are targeting for
growth.  We are pleased with this client win which continues the very
positive momentum in the business and further improves our revenue
visibility."

 

1.     Announced by the Company on 1 September 2020, 30 March 2021, 26
October 2021 and 9 December 2021

2.     TrialTrove search of industry sponsored PhII - IV Schizophrenia
Trials 2011 - 2021

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                         Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)

 Sally Jennings, Head of Marketing & Communications
 finnCap Ltd (NOMAD and Joint Broker)                     Tel: 020 7220 0500

 Geoff Nash / Simon Hicks                                 (Corporate Finance)

 Alice Lane / Charlotte Sutcliffe                         (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                   Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPUUWGUPPGMM